CN106728645A - 一种家畜催乳的中药复方组合物 - Google Patents
一种家畜催乳的中药复方组合物 Download PDFInfo
- Publication number
- CN106728645A CN106728645A CN201611242666.3A CN201611242666A CN106728645A CN 106728645 A CN106728645 A CN 106728645A CN 201611242666 A CN201611242666 A CN 201611242666A CN 106728645 A CN106728645 A CN 106728645A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- luffa
- rhizoma cyperi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 71
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 241001465754 Metazoa Species 0.000 title claims abstract description 16
- 150000001875 compounds Chemical class 0.000 title description 2
- 239000000463 material Substances 0.000 claims abstract description 27
- 239000009636 Huang Qi Substances 0.000 claims abstract description 21
- MUKYLHIZBOASDM-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid 2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound NC(=N)N(C)CC(O)=O.OCC(O)C(O)C(O)C(O)C(O)=O MUKYLHIZBOASDM-UHFFFAOYSA-N 0.000 claims abstract description 19
- 241001533104 Tribulus terrestris Species 0.000 claims abstract description 19
- 241001671219 Stachyurus Species 0.000 claims abstract description 18
- 241001074093 Echinopsis Species 0.000 claims abstract description 17
- 235000003956 Luffa Nutrition 0.000 claims abstract description 16
- 241000219138 Luffa Species 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 12
- 239000006071 cream Substances 0.000 claims description 10
- 239000003826 tablet Substances 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 238000002386 leaching Methods 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 235000014676 Phragmites communis Nutrition 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 10
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 244000050983 Luffa operculata Species 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 description 16
- 239000000341 volatile oil Substances 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 13
- 235000013336 milk Nutrition 0.000 description 13
- 239000008267 milk Substances 0.000 description 13
- 210000004080 milk Anatomy 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000219112 Cucumis Species 0.000 description 4
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000002175 menstrual effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 239000001116 FEMA 4028 Substances 0.000 description 3
- 208000019395 Lactation disease Diseases 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 206010042576 Suppressed lactation Diseases 0.000 description 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 3
- 229960004853 betadex Drugs 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 208000004396 mastitis Diseases 0.000 description 3
- 231100000862 numbness Toxicity 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 239000003390 Chinese drug Substances 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006651 lactation Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- -1 sublimed preparation Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010049077 Hernia pain Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 241000526657 Microchloa Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000290970 Tetrapanax papyrifer Species 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000037006 agalactosis Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种家畜催乳的中药组合物,由以下重量配比的中药原料药制备而成:小通草100‑300份、丝瓜络100‑200份、黄芪100‑200份、蒺藜100‑200份、漏芦100‑200份、香附50‑150份、甘草50‑150份。其各原料组分之间可以产生协同作用,相互间可增进疗效,见效快,无任何的毒副作用,并且该中药组合物药效稳定,不因时间过长而影响效果。
Description
技术领域:
本发明涉及一种家畜催乳的中药组合物,该中药由小通草、丝瓜络、黄芪、蒺藜、漏芦、香附、甘草制备而成,用于治疗母猪的气血亏虚、产后乳少或缺乳、乳汁不通等症状,促进家畜产后泌乳。
背景技术:
仔畜成活率低是困扰我国养殖业发展的重要问题之一。造成仔畜成活率低的原因较多,其中不可忽视的原因是母畜的泌乳量不足。长期以来,人们一直通过使用激素的方法来提高母畜的泌乳量,但随着越来越多的食品安全事件不断发生,药物残留和激素使用问题越来越受到重视。中药保持了各种成分的自然状态和生物活性,具有天然、毒副作用小、不产生抗药性等优点,中药势必成为替代激素来提高母畜泌乳的产品。
中医学理论认为,乳汁乃由血所化生,赖气以运行与控制。是否有乳汁,乳汁的多少、下乳是否通畅,都与母畜的脏腑气血有密切关系。母畜产后缺乳主要是因为母畜素体虚弱,气血生化之源不足,或产时失血过多,不能生化为乳汁;肝气郁结,乳汁运行受阻而致。分为气血虚弱和肝郁气滞两类,气血虚弱表现为产后乳汁稀少、质清或全无,乳房松软,脉细弱,以补血益气通乳;肝郁气滞主要表现为乳房胀硬,脉弦,以疏肝通经下乳。因此,治疗此类产后泌乳不足或缺失等症,宜补气养血,通经下乳。
根据气血不足、肝气郁结等导致的母畜乳汁量少、乳汁全无、乳房胀痛等临床症候,从“补气养血、通经下乳、活血调经”等方面入手,开发一种用于治疗猪的产后气血亏虚、产后乳汁不通、乳少或缺乳的中药组合物。
发明内容:
本发明提供一种家畜催乳的中药组合物,由以下重量配比的中药原料药制备而成:
小通草100-300份、丝瓜络100-200份、黄芪100-200份、蒺藜100-200份、漏芦100-200份、香附50-150份、甘草50-150份。
优选的,由以下重量配比的中药原料药制备而成:
小通草150-250份、丝瓜络120-180份、黄芪120-180份、蒺藜120-180份、漏芦120-180份、香附80-120份、甘草80-120份。
更优选的,由以下重量配比的中药原料药制备而成:
小通草200份、丝瓜络150份、黄芪150份、蒺藜150份、漏芦150份、香附100份、甘草100份。
本发明方中,小通草为君药,丝瓜络为臣药,黄芪、蒺藜、漏芦、香附为佐药,甘草为使药,各组分的作用如下:
小通草:味甘、淡,寒。归肺、胃经。清热、利尿、下乳,用于乳汁不下、小便不利,淋证。现代研究表明,通草具有通经下乳、抗炎、解热、利尿等作用,同时还能够调节免疫、抗氧化。
丝瓜络:味甘,平。归肺、胃、肝经。祛凤,通络,活血,下乳。用于痹痛拘挛,胸胁胀痛,乳汁不通,乳痈肿痛。可以疏通乳腺管,治疗产后乳汁不通,乳房硬结。现代药理研究表明,丝瓜络具有降血脂、抑制体重增加,抗炎、镇痛镇静、抗过敏及对保护心肌等作用。
黄芪:味甘,微温。归肺、脾经。补气升阳,固表止汗,利水消肿,生津养血,行滞通痹,托毒排脓,敛疮生肌。用于气虚乏力,食少便溏,中气下陷,久泻脱肛,便血崩漏,表虚自汗,气虚水肿,内热消渴,血虚萎黄,半身不遂,痹痛麻木,痈疽难溃,久溃不敛。现代医学研究表明,黄芪有增强机体免疫功能、保肝、利尿、抗衰老、抗应激、降压和较广泛的抗菌作用。黄芪不仅能扩张冠状动脉,改善心肌供血,提高免疫功能,而且能够延缓细胞衰老的进程。
蒺藜:味辛、苦,微温。归肝经。平肝解郁,活血祛风,明目,止痒。用于头痛眩晕,胸胁胀痛,乳闭乳痈,目赤翳障,风疹瘙痒。
漏芦:味苦,寒。归胃经。清热解毒,消痈,下乳,舒筋通脉。用于乳痈肿痛,痈疽发背,瘰疬疮毒,乳汁不通,湿痹拘挛。
香附:味辛、微苦、微甘,平。归肝、脾、三焦经。疏肝解郁,理气宽中,调经止痛。用于肝郁气滞,胸胁胀痛,疝气疼痛,乳房胀痛,脾胃气滞,脘腹痞闷,胀满疼痛,月经不调,经闭痛经。
甘草:味甘,平。归心、肺、脾、胃经。补脾益气,淸热解毒,祛痰止咳,缓急止痛,调和诸药。用于脾胃虚弱,倦怠乏力,心悸气短,咳嗽痰多,脘腹、四肢挛急疼痛,痈肿疮毒,缓解药物毒性、烈性。
以上组成中,药物重量是以生药计算的,在生产时可按照相应比例增大或减少,如大规模生产可以以公斤为单位,或以吨为单位,小规模生产也可以以毫克为单位,重量可以增大或者减小,但各组成之间的生药材重量配比的比例不变。
以上配比的比例是经过科学筛选得到的,对于特殊情况,如重症或轻症,肥胖或瘦小的,可以相应调整组成的量的配比,增加或减少不超过100%,药效不变。
以上组成中的单味中药,尤其是臣药和佐药,也可以被适当的具有相同药性的中药替换,替换后的中药制剂其药物作用不变。
本发明的中药组合物,在制备成药物制剂时,必要时可加入药物可接受的载体,按照制剂学的常规技术制备。其中的中药部分可以采用中药原料药制备得到,也可以通过共同提取中药原料得到,也可以通过其他方式得到,如:通过粉碎、压榨、煅烧、研磨、过筛、渗漉、萃取、水提、醇提、酯提、酮提、层析等方法得到中药活性物质、这些中药活性物质可以是浸膏形式的物质,可以是干浸膏也可以是流浸膏,根据制剂的不同需要决定制成不同的浓度。
本发明的药物制剂形式,以单位剂量形式存在,所述单位剂量形式是指制剂的单位,如片剂的每片,胶囊的每粒胶囊,颗粒剂每袋等。
本发明的中药制剂可以是任何可药用的剂型,这些剂型包括:片剂、胶囊剂、颗粒剂、丸剂、散剂、膏剂、丹剂、粉剂、溶液剂、注射剂、栓剂、喷雾剂、滴剂、贴剂。本发明的制剂,优选的是口服剂型,如:胶囊剂、片剂、口服液、颗粒剂、丸剂、散剂、丹剂、膏剂等。
本发明的中药组合物,其口服给药的制剂可含有常用的赋形剂,诸如粘合剂、填充剂、稀释剂、压片剂、润滑剂、崩解剂、着色剂、调味剂和湿润剂。适用的填充剂包括淀粉、蔗糖、纤维素、甘露糖醇、乳糖和其它类似的填充剂。适宜的崩解剂包括淀粉、聚乙烯吡咯烷酮和淀粉衍生物,例如羟基乙酸淀粉钠。适宜的润滑剂包括,例如硬脂酸镁。可通过混合,填充,压片等常用的方法制备固体口服组合物。进行反复混合可使活性物质分布在整个使用大量填充剂的那些组合物中;常用的辅料成分包括:甘露醇、山梨醇、焦亚硫酸钠、亚硫酸氢钠、硫代硫酸钠、盐酸半胱氨酸、巯基乙酸、蛋氨酸、维生素C、EDTA二钠、EDTA钙钠,一价碱金属的碳酸盐、醋酸盐、磷酸盐或其水溶液、盐酸、醋酸、硫酸、磷酸、氨基酸、氯化钠、氯化钾、乳酸钠、木糖醇、麦芽糖、葡萄糖、果糖、右旋糖苷、甘氨酸、淀粉、蔗糖、乳糖、甘露糖醇、硅衍生物、纤维素及其衍生物、藻酸盐、明胶、聚乙烯吡咯烷酮、甘油、土温80、琼脂、碳酸钙、碳酸氢钙、表面活性剂、聚乙二醇、环糊精、β-环糊精、磷脂类材料、高岭土、滑石粉、硬脂酸钙、硬脂酸镁等。
本发明的制剂在使用时根据情况确定用法用量,可以每日服1-2次,每次按每公斤体重0.5-5g剂量。
本发明进一步提供制备方法:取香附加6~12倍量水,蒸馏2~8小时提取挥发油,挥发油另器收集,挥发油与β-环糊精(1:10)包合,40℃干燥,提取后的药液,另器贮存。药渣与小通草、丝瓜络、黄芪、蒺藜、漏芦、甘草等6味药材加8~12倍量水煎煮1~3次,每次1~3小时,合并煎煮液,滤过,静置过夜、滤取上清液,减压浓缩至相对密度1.21~1.27(50℃),干燥成干膏。干膏粉碎成细粉,过100目筛,加入挥发油β-环糊精包合物,加入适量辅料,混匀,制备胶囊剂、散剂、颗粒剂或片剂。
经过药学研究证实,本制剂工艺稳定,适合大生产。
具体实施方式:
以下通过实施例进一步说明本发明,但不作为对本发明的限制。
实施例1
一种家畜催乳的中药组合物,其是由下列重量份的中药原料组成:小通草200g、丝瓜络150g、黄芪150g、蒺藜150g、漏芦150g、香附100g、甘草100g。
取处方量的香附加6~12倍量水浸泡0.5小时,蒸馏2~8小时,提取挥发油,收集挥发油,挥发油与β-环糊精(1:10)包合,备用。药渣与小通草、丝瓜络、黄芪、蒺藜、漏芦、甘草等6味药材加8~12倍量水煎煮1~3次,每次1~3小时,合并煎煮液,滤过,与上述药液合并,静置过夜、滤取上清液,减压浓缩至相对密度1.21~1.27(50℃)、干燥成干膏。干膏粉碎成细粉,过100目筛,加入挥发油β-环糊精包合物,加入适量辅料,混匀,制备胶囊剂、散剂、颗粒剂或片剂。
实施例2
一种家畜催乳的中药组合物,其是由下列重量份的中药原料组成:小通草220g、丝瓜络180g、黄芪120g、蒺藜130g、漏芦120g、香附120g、甘草110g。
取处方量的香附加6~12倍量水浸泡0.5小时,蒸馏2~8小时,提取挥发油,挥发油另器收集,挥发油与β-环糊精(1:10)包合,备用。药渣与小通草、丝瓜络、黄芪、蒺藜、漏芦、甘草等6味药材加8~12倍量水煎煮1~3次,每次1~3小时,合并煎煮液,滤过,与上述药液合并,静置过夜、滤取上清液,减压浓缩至相对密度1.21~1.27(50℃)、干燥成干膏。干膏粉碎成细粉,过100目筛,加入挥发油β-环糊精包合物,加入适量辅料,混匀,制备胶囊剂、散剂、颗粒剂或片剂。
实施例3
一种家畜催乳的中药组合物,其是由下列重量份的中药原料组成:小通草250g、丝瓜络200g、黄芪200g、蒺藜100g、漏芦100g、香附100g、甘草50g。
称取处方量的香附,加6~12倍量水,蒸馏2~8小时,提取挥发油,挥发油另器收集,挥发油与吐温-80以1:3比例混合,备用;提取后的药液,另器贮存;提取后的药渣与小通草、丝瓜络、黄芪、蒺藜、漏芦、甘草6味药材加8~12倍量水煎煮1~3次,每次1~3小时,合并煎煮液,滤过,静置过夜、滤取上清液,与步骤1)得到的药液合并,减压浓缩至相对密度1.05~1.15(50℃)的清膏,加乙醇使含醇量至60%~70%,静置24~48小时,过滤,滤液回收乙醇至无醇味,加1-3‰的防腐剂,与挥发油吐温-80的混合物混合均匀,加水至1000ml,制成口服液。
实施例4
一种家畜催乳的中药组合物,其是由下列重量份的中药原料组成:小通草300g、丝瓜络150g、黄芪150g、蒺藜150g、漏芦100g、香附100g、甘草50g。
称取上述处方量的药味,干燥,粉碎,过100目筛,制成散剂。
本发明的一种家畜催乳的中药组合物主要药效学实验:
选择分娩时间相近、体型较好、体质健康、胎次一致、体重差异不大的40头二元杂交母猪,随机分成4组,分别为对照组和实验1、2、3组。试验前猪舍进行消毒,母猪日喂2次,从预产期前7d开始,实验组母猪饲料中加入适量中药,每100g本发明的中药组合物拌料1kg饲喂。实验1组为实施例1中的中药组合物,实验2组为实施例1缺君药的中药组合物,实验3组为实施例1缺臣药的中药组合物,其它方案按照猪场常规管理和免疫程序进行。分别测定仔猪初生窝重、20日龄窝重和断奶窝重,逐一作好记录。
表1本发明中中药对仔猪初生窝重和20日龄窝重及断奶窝重的影响
注:同列数字后标注不同字母者表示差异显著(P<0.05),标注相同字母者表示差异不显著(P>0.05)。
从实验结果可知,在母猪饲料中添加中药后,实验1组仔猪20日龄窝重比对照组提高25%(P<0.05),实验1组仔猪断奶窝重比对照组提高16%(P<0.05)。实验2组仔猪20日龄窝重比对照组提高3.8%(P>0.05),实验2组仔猪断奶窝重比对照组提高3%(P>0.05)。实验3组仔猪20日龄窝重比对照组提高17%(P<0.05),实验3组仔猪断奶窝重比对照组提高12%(P<0.05)。可见本发明的中药组合物组方合理,在母猪饲料中添加适量本中药组合物对仔猪20日龄窝重和断奶窝重有显著的提高,说明该中药组合物对母猪泌乳性能有明显的改善作用。
本发明中的促进家畜产后泌乳的中药组合物的制备工艺流程简单,该中药对母猪泌乳性能有明显改善作用。本发明意外的发现,本发明各组份的搭配具有协同增效作用。
Claims (6)
1.一种家畜催乳的中药组合物,由以下重量配比的中药原料药制备而成:
小通草100-300份、丝瓜络100-200份、黄芪100-200份、蒺藜100-200份、漏芦100-200份、香附50-150份、甘草50-150份。
2.根据权利要求1所述的组合物,由以下重量配比的中药原料药制备而成:
小通草150-250份、丝瓜络120-180份、黄芪120-180份、蒺藜120-180份、漏芦120-180份、香附80-120份、甘草80-120份。
3.根据权利要求1所述的组合物,由以下重量配比的中药原料药制备而成:
小通草200份、丝瓜络150份、黄芪150份、蒺藜150份、漏芦150份、香附100份、甘草100份。
4.根据权利要求1所述的组合物,是任何可药用的剂型。
5.根据权利要求4所述的组合物,所述剂型选自:片剂、胶囊剂、颗粒剂、丸剂、散剂、膏剂、丹剂、粉剂、溶液剂、注射剂、栓剂、喷雾剂、滴剂、贴剂。
6.权利要求1所述的组合物的制备方法,步骤如下:取小通草、丝瓜络、黄芪、蒺藜、漏芦、香附、甘草等7位药材加8~12倍量水煎煮1~3次,每次1~3小时,合并煎煮液,滤过,静置过夜、滤取上清液,减压浓缩至相对密度1.21~1.27(50℃)、干燥成干膏。将干膏粉碎成细粉,过100目筛,加入适量辅料,混匀,制备胶囊剂、散剂、颗粒剂或片剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611242666.3A CN106728645A (zh) | 2016-12-29 | 2016-12-29 | 一种家畜催乳的中药复方组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611242666.3A CN106728645A (zh) | 2016-12-29 | 2016-12-29 | 一种家畜催乳的中药复方组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106728645A true CN106728645A (zh) | 2017-05-31 |
Family
ID=58923775
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611242666.3A Pending CN106728645A (zh) | 2016-12-29 | 2016-12-29 | 一种家畜催乳的中药复方组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106728645A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115998790A (zh) * | 2021-10-22 | 2023-04-25 | 洛阳瑞华动物保健品有限公司 | 一种提高母畜泌乳的中药制剂 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1823885A (zh) * | 2005-12-27 | 2006-08-30 | 黄开启 | 一种用于治疗产后乳汁不下或稀少的新制剂 |
CN103720746A (zh) * | 2012-10-11 | 2014-04-16 | 贠钦亮 | 一种治疗产后无乳的中药散剂 |
CN103933331A (zh) * | 2014-04-01 | 2014-07-23 | 回音必集团安徽制药有限公司 | 一种麦当乳通颗粒及其制备工艺 |
-
2016
- 2016-12-29 CN CN201611242666.3A patent/CN106728645A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1823885A (zh) * | 2005-12-27 | 2006-08-30 | 黄开启 | 一种用于治疗产后乳汁不下或稀少的新制剂 |
CN103720746A (zh) * | 2012-10-11 | 2014-04-16 | 贠钦亮 | 一种治疗产后无乳的中药散剂 |
CN103933331A (zh) * | 2014-04-01 | 2014-07-23 | 回音必集团安徽制药有限公司 | 一种麦当乳通颗粒及其制备工艺 |
Non-Patent Citations (1)
Title |
---|
陈颖等: "饲料中添加增乳散提高仔猪存活率", 《中国兽医杂志》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115998790A (zh) * | 2021-10-22 | 2023-04-25 | 洛阳瑞华动物保健品有限公司 | 一种提高母畜泌乳的中药制剂 |
CN115998790B (zh) * | 2021-10-22 | 2024-02-09 | 洛阳瑞华动物保健品有限公司 | 一种提高母畜泌乳的中药制剂 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105497879A (zh) | 一种抗应激改善产品风味的中药复方 | |
CN105076893A (zh) | 一种奶牛饲料及其制备方法 | |
CN101549101B (zh) | 一种用于治疗尘肺病和耐药性肺结核病的中药及制备方法 | |
CN102671178B (zh) | 一种治疗肾病综合症及尿毒症的中药组合物配制方法及应用 | |
CN104013789A (zh) | 一种通便排毒的中药制剂及其制备方法 | |
CN102106965B (zh) | 一种治疗软组织急性损伤的组合物及其应用 | |
CN106994141B (zh) | 一种治疗便秘的中药组合物及其制备方法 | |
CN103960542B (zh) | 一种用于防治猪附红细胞体病的饲料和中药组合物 | |
CN105535094A (zh) | 一种促进畜禽和鱼类生产性能的中药组合物 | |
CN104825821A (zh) | 一种治疗糖尿病的药物及其制备方法 | |
CN106728645A (zh) | 一种家畜催乳的中药复方组合物 | |
CN106729283A (zh) | 一种用于家畜催情促孕的中药组合物及其制备方法 | |
CN105902867B (zh) | 一种降三高的植物药组合物及其制备方法 | |
CN105213758A (zh) | 一种治疗慢性肺炎的中药组合物及其制备方法 | |
CN104524359B (zh) | 一种中药组合物、其制备方法及应用 | |
CN104162090B (zh) | 一种药物组合物及其制备方法 | |
CN107737250A (zh) | 一种高血压中药组合物及其制备方法 | |
CN103751692B (zh) | 一种海狗鞭特补胶囊及其制备方法 | |
CN107362301A (zh) | 香苓开胃颗粒 | |
CN106389748A (zh) | 一种促进家畜产后泌乳的中药复方及其制备方法 | |
CN106039120A (zh) | 侧子祛湿药酒 | |
CN105056160A (zh) | 一种治疗奶牛缺乳症的药物组合物及其制备方法 | |
CN104352862A (zh) | 一种含余甘子的治疗糖尿病的中药组合物 | |
CN103520408A (zh) | 一种健脑补肾保健品及其制备方法 | |
CN104435141A (zh) | 一种含鬼箭羽的治疗糖尿病的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170531 |
|
RJ01 | Rejection of invention patent application after publication |